GO:1901343 negative regulation of vasculature development: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901343 (negative regulation of vasculature development) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of vasculature development.
• It is a biological_process term that acts as a brake on angiogenesis and vessel maturation, and its failure contributes to vascular anomalies, tumor hypervascularity, and aberrant midline vessel formation [1,3,4].
• Key molecular players include EPHB4 and RASA1, which together dampen Ras-MAPK signaling in endothelial cells to restrain vessel growth.
• The notochord secretes negative signals that restrict midline vascular development, showing that anatomical patterning depends on active inhibition of vessel formation.
• Loss of negative regulation can produce EPHB4- and RASA1-related vascular anomalies in humans, making this GO term clinically actionable.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate genes causally restrain vasculature development [1,3].
Description
GO:1901343, negative regulation of vasculature development, is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of vasculature development. Vasculature development encompasses the formation, remodeling, and maturation of blood vessels, and it is normally balanced by positive and negative regulatory inputs. When negative regulation is weakened, vessels can form excessively, ectopically, or with abnormal architecture, as seen in tumor angiogenesis and vascular malformations [1,3]. Conversely, excessive negative regulation can impair tissue perfusion and contribute to ischemic or degenerative phenotypes. Understanding this term therefore matters for cancer biology, vascular anomaly research, and developmental patterning studies [1,3,4]. The term is not a single pathway but a collection of inhibitory processes, including ligand-receptor signaling brakes, secreted midline repellents, and intracellular feedback loops that converge on endothelial cell behavior [3,4]. This article synthesizes the QuickGO definition with verified PubMed literature to explain what happens during negative regulation of vasculature development, which genes are involved, and how CRISPR-based models can be used to study it [1,3,4].
negative regulation of vasculature development At A Glance
| GO ID | GO:1901343 |
|---|---|
| GO term | negative regulation of vasculature development |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of vasculature development. |
| Synonyms | down regulation of vascular system development; down-regulation of vascular system development; downregulation of vascular system development; down regulation of vasculature development; down-regulation of vasculature development; downregulation of vasculature development; inhibition of vascular system development; inhibition of vasculature development; negative regulation of vascular system development |
| Major function | Restrains angiogenesis and vessel maturation to maintain appropriate vascular density and patterning. |
| Representative regulators | EPHB4, RASA1, and notochord-derived midline inhibitory signals [3,4]. |
| Clinical relevance | Dysregulation is linked to vascular anomalies, tumor hypervascularity, and abnormal midline vessel formation [1,3,4]. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, and endothelial signaling assays [1,3]. |
What Is GO:1901343?
In plain terms, GO:1901343 describes any process that slows down, blocks, or prevents the development of blood vessels. It is the opposite of pro-angiogenic signaling: instead of promoting sprouting, migration, and tube formation, it restrains those activities so that vessel growth stays proportionate to tissue needs. The QuickGO definition states that it is any process that stops, prevents or reduces the frequency, rate or extent of vasculature development. This includes extracellular cues, receptor-mediated inhibitory signaling, and intracellular feedback that limits endothelial proliferation, migration, or survival [1,3,4]. Because it is a biological_process term, it is assigned to gene products and pathways whose normal function is to suppress vessel formation rather than to drive it.
Why Is negative regulation of vasculature development Important in Cell Biology?
Negative regulation of vasculature development is important because blood vessel growth must be tightly controlled: too little vessel formation causes ischemia, while too much or mispatterned vessel formation drives tumor progression, vascular malformations, and developmental defects [1,3,4]. The term provides a framework for identifying the molecular brakes that keep angiogenesis in check, and for understanding how their loss produces disease [1,3]. In cancer, normalization of the vasculature depends on restoring balance between pro- and anti-angiogenic signals, a concept directly tied to negative regulation of vasculature development. In vascular anomalies, mutations in EPHB4 and RASA1 disrupt a negative feedback module that normally suppresses Ras-MAPK signaling in endothelial cells. In embryonic patterning, the notochord actively inhibits midline vessel formation, demonstrating that negative regulation is a developmental necessity rather than a passive default. Studying this GO term therefore connects basic vascular biology to therapeutic strategies in oncology and vascular medicine [1,3].
• Maintains vascular homeostasis by preventing excessive or ectopic vessel growth.
• Restrains tumor angiogenesis and supports the concept of vascular normalization for cancer therapy.
• Prevents vascular malformations caused by loss of EPHB4-RASA1-mediated inhibition of Ras-MAPK signaling.
• Controls midline vascular patterning through notochord-derived inhibitory signals.
• Balances pro-angiogenic cues such as VEGF-driven sprouting with anti-angiogenic feedback.
• Provides mechanistic targets for anti-angiogenic and vascular-normalizing drugs.
• Helps explain why some vascular anomalies are caused by gain-of-function or loss-of-function mutations in inhibitory pathways.
• Guides developmental biology studies of organ-specific vessel patterning.
• Supports CRISPR-based causal testing of candidate inhibitory genes in endothelial cells [1,3].
• Links vascular biology to metabolic and skeletal tissue interactions where vessel growth must be constrained.
What Happens During negative regulation of vasculature development?
Initiation by inhibitory cues
In simple terms: The process starts when a signal tells endothelial cells to slow down or stop forming new vessels.
Negative regulation of vasculature development is initiated by extracellular or cell-contact cues that oppose pro-angiogenic signaling. These cues can be soluble factors, matrix-bound molecules, or membrane ligands that engage inhibitory receptors on endothelial cells. In the embryo, the notochord provides a classic example: it secretes negative signals that restrict vessel formation along the midline, preventing vessels from invading territories where they do not belong. This initiation step is essential because it sets the spatial and temporal boundaries of vessel growth.
Receptor-mediated suppression of Ras-MAPK signaling
In simple terms: Certain receptors act like brakes on a growth signal inside endothelial cells.
A well-characterized mechanism is EPHB4-RASA1-mediated negative regulation of Ras-MAPK signaling in the vasculature. EPHB4 is a receptor tyrosine kinase that, together with the GTPase-activating protein RASA1, dampens Ras-MAPK pathway activity in endothelial cells. This inhibition reduces endothelial proliferation and sprouting, thereby restraining vasculature development. Loss of this brake leads to excessive Ras-MAPK signaling and is implicated in EPHB4- and RASA1-related vascular anomalies in humans.
Feedback attenuation of pro-angiogenic pathways
In simple terms: The same pathways that promote vessel growth also trigger their own off-switches.
Negative regulation of vasculature development also operates through intracellular feedback loops that attenuate pro-angiogenic signaling. For example, sustained activation of growth factor receptors can induce negative feedback regulators that reduce downstream signaling intensity and duration. This feedback ensures that angiogenesis is self-limiting and that vessels mature rather than continuously sprout. The balance between pro-angiogenic drivers and these feedback brakes determines the final vascular architecture.
Restriction of endothelial migration and tube formation
In simple terms: Even when endothelial cells are present, negative signals can stop them from moving and forming tubes.
At the cellular level, negative regulation of vasculature development reduces endothelial cell migration, proliferation, and tube formation [1,3]. Inhibitory signaling can alter cytoskeletal dynamics and cell adhesion, preventing endothelial cells from organizing into new capillary structures. In midline patterning, notochord-derived signals restrict endothelial migration into the midline region, showing that negative regulation acts on cell movement as well as growth. These cellular effects translate into reduced vessel density and more organized vascular networks.
Integration with tissue metabolic and developmental cues
In simple terms: Vessel growth is also tuned by the metabolic needs and developmental stage of the surrounding tissue.
Negative regulation of vasculature development does not operate in isolation; it is integrated with tissue metabolic and developmental cues. Skeletal and metabolic tissues, for instance, coordinate vessel growth with bone formation and energy status, and negative regulation helps match vascular supply to tissue demand. This integration ensures that vessels are not formed where or when they are not needed. The interplay between metabolic signals and vascular inhibitors is an active area of research.
Key Genes Involved in GO:1901343 negative regulation of vasculature development
The following genes and proteins have been experimentally linked to negative regulation of vasculature development or to closely related vascular inhibitory mechanisms in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EPHB4 | Receptor tyrosine kinase that, with RASA1, suppresses Ras-MAPK signaling in endothelial cells | Central to EPHB4-related vascular anomalies and a target for CRISPR knockout and point-mutation studies |
| RASA1 | GTPase-activating protein that dampens Ras signaling downstream of EPHB4 | Loss-of-function mutations cause RASA1-related vascular anomalies; key for knock-in and knockout models |
| VHL | Tumor suppressor involved in oxygen sensing and regulation of angiogenic signaling | Von Hippel-Lindau disease models test how loss of VHL alters vascular regulation |
| PROX1 | Transcription factor regulating endothelial identity and blood-brain barrier properties | Studied for its role in endothelial specialization and vessel behavior in the CNS |
| FUSCA3 | Plant transcription factor regulating seed development | Provides a comparative developmental model for studying regulatory gene expression |
| Notochord-derived signals | Secreted inhibitors that restrict midline vascular development | Used to study embryonic patterning of vessels and negative regulation in vivo |
| VEGF pathway components | Pro-angiogenic drivers whose activity is balanced by negative regulators | Targets for testing how negative regulation counteracts angiogenesis |
| Ras-MAPK pathway components | Intracellular signaling module suppressed by EPHB4-RASA1 | Readouts for measuring loss of negative regulation in endothelial cells |
| EPHB4 ligands (ephrin-B2) | Membrane ligands that activate EPHB4 inhibitory signaling | Used in co-culture and knock-in experiments to activate the brake |
| Endothelial junctional proteins | Maintain vessel integrity and respond to inhibitory cues | Assessed in permeability and barrier assays |
| Hypoxia-inducible factors | Transcription factors that drive angiogenic gene expression and are modulated by VHL | Studied in VHL-related models of vascular dysregulation |
| Metabolic regulators of skeletal cells | Coordinate bone formation with vascular supply | Relevant to tissue-specific negative regulation of vessel growth |
How Is negative regulation of vasculature development Regulated?
Negative regulation of vasculature development is itself regulated at multiple levels. The EPHB4-RASA1 module provides a receptor-proximal brake on Ras-MAPK signaling, and its activity depends on ligand availability and receptor expression. Pro-angiogenic stimuli such as VEGF can transiently overcome this brake, but sustained negative feedback restores quiescence. In developmental contexts, the notochord secretes inhibitory signals that pattern midline vessels, showing that anatomical sources of negative regulation are spatially restricted. Metabolic and developmental cues also influence how strongly negative regulation is applied in a given tissue. Together, these layers ensure that vessel growth is context-dependent and self-limiting [1,3,4].
negative regulation of vasculature development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPHB4 | EPHB4-related vascular anomalies | Endothelial knockout and point-mutation models |
| RASA1 | RASA1-related vascular anomalies | Knock-in of patient mutations and knockout in endothelial cells |
| VHL | Von Hippel-Lindau disease | VHL knockout cell models and hypoxia assays |
| PROX1 | Blood-brain barrier disruption in the CNS | Endothelial overexpression and knockout models |
| Notochord signals | Midline vascular patterning defects | Embryonic explant and in vivo perturbation models |
Vascular anomalies and EPHB4-RASA1 dysfunction
Mutations that impair EPHB4-RASA1-mediated negative regulation of Ras-MAPK signaling cause vascular anomalies in humans. Loss of this brake leads to excessive endothelial signaling and abnormal vessel formation. These conditions illustrate how a failure of negative regulation of vasculature development directly translates into human disease. Experimental models that restore or mimic the brake are therefore of therapeutic interest.
Cancer and tumor angiogenesis
In cancer, the balance between pro-angiogenic and anti-angiogenic signals is shifted toward vessel growth, and negative regulation of vasculature development is often compromised. Normalization of the vasculature for treatment of cancer and other diseases depends on restoring this balance. Anti-angiogenic strategies aim to reinstate negative regulatory mechanisms or their downstream effects. Understanding GO:1901343 helps identify which inhibitory pathways are lost in tumors.
Developmental midline vascular patterning defects
The notochord negatively regulates midline vascular development, and disruption of this inhibitory signal can lead to abnormal vessel patterning. Such defects highlight the importance of negative regulation in embryonic development. Studying these mechanisms informs both developmental biology and congenital vascular disorders.
Von Hippel-Lindau disease and oxygen-sensing pathways
Von Hippel-Lindau disease involves dysregulation of oxygen-sensing and angiogenic pathways, indirectly affecting negative regulation of vasculature development. Loss of VHL function alters the normal restraint on angiogenic signaling. This connection links the GO term to hereditary cancer syndromes and hypoxia-driven vascular pathology.
From negative regulation of vasculature development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EPHB4 increase endothelial Ras-MAPK signaling and vessel growth? | EPHB4 knockout endothelial cells |
| Do patient-derived RASA1 point mutations impair negative regulation? | RASA1 point-mutation knock-in cells |
| Can restoring EPHB4-RASA1 signaling normalize vascular anomalies? | EPHB4 or RASA1 knock-in / overexpression models |
| How does VHL loss affect angiogenic restraint? | VHL knockout cell lines and hypoxia readouts |
| What is the role of PROX1 in endothelial barrier regulation? | PROX1 overexpression and knockout endothelial models |
| How do notochord signals restrict midline vessels? | Embryonic perturbation and reporter models |
How to Study the negative regulation of vasculature development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on vessel growth | Testing candidate negative regulators in endothelial cells |
| Point-mutation knock-in | Functional impact of patient variants | Modeling EPHB4- and RASA1-related anomalies |
| Phospho-protein Western blot | Ras-MAPK signaling activity | Assessing loss of EPHB4-RASA1 brake |
| Endothelial migration assay | Cell movement capacity | Measuring functional consequences of negative regulation |
| Embryonic imaging | Vessel patterning in vivo | Studying midline vascular development |
| RNA sequencing | Transcriptional changes | Mapping downstream effects of inhibitory pathways |
| Hypoxia reporter assay | Oxygen-sensing pathway activity | VHL-related vascular studies |
| Barrier permeability assay | Endothelial barrier function | PROX1-related blood-brain barrier research |
CRISPR knockout and point-mutation screens
CRISPR knockout and point-mutation approaches allow causal testing of genes hypothesized to mediate negative regulation of vasculature development. By disrupting EPHB4 or RASA1, researchers can measure changes in Ras-MAPK signaling and endothelial behavior. Point mutations can mimic patient variants to assess their functional impact. These methods are foundational for linking genotype to vascular phenotype.
Endothelial signaling assays
Western blotting and phospho-protein assays measure Ras-MAPK activity downstream of EPHB4-RASA1. These readouts quantify whether negative regulation is intact or lost. They are typically combined with proliferation and migration assays to assess functional consequences. Such assays are standard in vascular biology laboratories.
Imaging of vascular patterning
Imaging approaches visualize vessel density, sprouting, and midline patterning in embryos and tissues. They can reveal ectopic or excessive vessel formation when negative regulation is disrupted. Reporter lines and dye perfusion are commonly used to assess vascular architecture. Imaging is essential for validating in vitro findings in vivo.
Transcriptomic and pathway analysis
RNA sequencing and pathway analysis identify gene expression changes when negative regulators are lost. These methods help map the downstream consequences of disrupted inhibitory signaling. They can also reveal compensatory feedback mechanisms. Integrating transcriptomics with functional assays strengthens causal inference.
How CRISPR Can Be Used to Study GO:1901343 negative regulation of vasculature development
Knockout
CRISPR knockout of EPHB4 or RASA1 removes the negative regulation of Ras-MAPK signaling, leading to increased endothelial activation. This approach is used to test whether a gene is required to restrain vasculature development. Knockout endothelial cells can be compared with wild-type controls in proliferation, migration, and signaling assays. Such experiments provide direct causal evidence for the gene's role in GO:1901343.
Point Mutation
Point-mutation knock-in models introduce specific patient-derived variants into EPHB4 or RASA1. These models distinguish loss-of-function from gain-of-function effects and reveal how subtle changes impair negative regulation. They are particularly valuable for vascular anomalies where missense mutations are common. Functional readouts include Ras-MAPK activity and endothelial behavior.
Knock-in
Knock-in of tagged or reporter alleles allows visualization and quantification of negative regulators in endothelial cells. Tagged EPHB4 or RASA1 can be used to study protein localization, stability, and interactions. Knock-in models also enable rescue experiments to confirm that a specific gene product mediates the inhibitory effect. These approaches strengthen mechanistic conclusions about GO:1901343.
Overexpression
Overexpression of negative regulators such as EPHB4 or RASA1 can enhance the brake on vasculature development. This is useful for testing whether increasing inhibitory signaling can normalize excessive vessel growth. Overexpression models complement knockout studies by providing gain-of-function evidence. They are also used to validate therapeutic strategies aimed at restoring negative regulation.
How EDITGENE Supports negative regulation of vasculature development Research
Researchers studying negative regulation of vasculature development-related genes often need to determine whether a candidate gene is causally involved in restraining vessel growth, and whether specific patient variants alter that function. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point-mutation, knock-in, and overexpression experiments in endothelial and other relevant cell types. These services help translate genetic hypotheses into functional evidence for GO:1901343.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of vasculature development research.
Frequently Asked Questions About negative regulation of vasculature development
What is GO:1901343 negative regulation of vasculature development?
GO:1901343 is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of vasculature development.
What genes are involved in negative regulation of vasculature development?
Key genes include EPHB4 and RASA1, which together suppress Ras-MAPK signaling in endothelial cells, as well as VHL and PROX1 in related vascular contexts [3,7,8].
How does EPHB4-RASA1 signaling inhibit vessel growth?
EPHB4, with RASA1, dampens Ras-MAPK pathway activity in endothelial cells, reducing proliferation and sprouting and thereby restraining vasculature development.
Why is negative regulation of vasculature development important in cancer?
In cancer, loss of negative regulation contributes to excessive tumor angiogenesis, and restoring the balance is a goal of vascular normalization strategies.
What diseases are linked to defective negative regulation of vasculature development?
EPHB4- and RASA1-related vascular anomalies, Von Hippel-Lindau disease, and abnormal midline vascular patterning are linked to defective negative regulation [3,4,7].
How can CRISPR be used to study GO:1901343?
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes that restrain vessel growth.
What experimental models are suitable for studying negative regulation of vasculature development?
Endothelial knockout and knock-in cells, embryonic imaging models, and hypoxia reporter assays are commonly used [3,4,7].
Does the notochord regulate midline vascular development?
Yes, the notochord provides negative signals that restrict midline vascular development in embryos.
What methods measure negative regulation of vasculature development?
Phospho-protein assays, migration assays, RNA sequencing, and imaging of vascular patterning are typical methods [1,3,4].
How does EDITGENE support research on negative regulation of vasculature development?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services for vascular research [1,3].
Conclusion
GO:1901343 negative regulation of vasculature development captures the essential brakes that keep blood vessel growth proportionate and correctly patterned. From EPHB4-RASA1-mediated suppression of Ras-MAPK signaling to notochord-derived midline inhibitors, these mechanisms protect against vascular anomalies, tumor hypervascularity, and developmental defects [1,3,4]. Studying this term requires causal experimental models, and CRISPR-based knockout, point-mutation, knock-in, and overexpression approaches are well suited to that task. By combining functional assays with transcriptomic and imaging readouts, researchers can clarify how negative regulation is lost in disease and how it might be restored therapeutically [1,3].
References
- 1. Goel S et al.. 2011. Normalization of the vasculature for treatment of cancer and other diseases.. Physiol Rev 91(3):1071-121 PMID: 21742796
- 2. Stegen S et al.. 2024. Metabolic regulation of skeletal cell fate and function.. Nat Rev Endocrinol 20(7):399-413 PMID: 38499689
- 3. Chen D et al.. 2023. EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans.. Pharmaceuticals (Basel) 16(2) PMID: 37259315
- 4. Reese DE et al.. 2004. Negative regulation of midline vascular development by the notochord.. Dev Cell 6(5):699-708 PMID: 15130494
- 6. Roscoe TJ et al.. 2019. Regulation of FUSCA3 Expression During Seed Development in Arabidopsis.. Plant Cell Physiol 60(2):476-487 PMID: 30462310
- 7. Sano T et al.. 2003. Von Hippel-Lindau disease.. Microsc Res Tech 60(2):159-64 PMID: 12539169
- 8. González-Hernández S et al.. 2026. Endothelial PROX1 induces blood-brain barrier disruption in the central nervous system.. JCI Insight 11(1) PMID: 41480750
